hn.today

GLP-1 may slow biological aging

universityofcalifornia.edu158 points146 comments
Screenshot of GLP-1 may slow biological aging

A randomized, double-blind, placebo-controlled trial in 108 adults with HIV-associated lipohypertrophy tested weekly semaglutide injections and found that the drug slowed biological aging across multiple DNA methylation-based epigenetic clocks. Compared with placebo over 32 weeks, semaglutide reduced the pace of aging by 9% on the DunedinPACE clock and produced significant reductions on PCGrimAge, a predictor linked to all-cause mortality and age-related disease. Effects were broad, spanning signatures tied to inflammation and function of blood, brain, heart, kidney, liver and metabolic systems. Researchers attribute these changes to reduced inflammation and metabolic stress, decreased visceral and ectopic fat, lowered chronic immune activation common in people with HIV, and possible cellular reprogramming across organs.

A related 24-week pilot study in people with HIV and MASLD reported complementary findings: DunedinPACE slowed for 42% of participants, PCGrimAge improved in 34%, and PCDNAmTL indicated telomere length increases in about 49%, with those individuals showing better walking speed. Investigators emphasize that semaglutide is not reversing aging but altering biological processes associated with aging, and they call for larger trials to confirm durability, optimize dosing and test combinations with lifestyle interventions. Plans include individualized epigenetic “aging dashboards” to guide personalized therapies.

Read on universityofcalifornia.edu146 comments on Hacker News

Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.

More in Science

The daily digest

Today's best Hacker News stories, summarized and screenshotted, one email a day.